|
|
News Breaks | | | | January 22, 2013 | | 09:04 EDT |  | GALT | Galectin Therapeutics announces preclinical data on anti-galectin therapy
Galectin Therapeutics announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease. Treatment of diabetic mice with GR-MD-02 was found to reverse the primary kidney disease associated with diabetes, called diabetic nephropathy, the leading cause of kidney failure, dialysis and kidney transplant. GR-MD-02 is the Company's lead galectin inhibitor in development for the treatment of liver fibrosis, including non-alcoholic steatohepatitis, or NASH, liver disease. In the preclinical study, diabetic mice developed histological findings consistent with diabetic nephropathy, consisting of glomerular lesions in the form of diffuse mesangial matrix accumulation and proliferation. The kidneys of the diabetic mice also showed fibrosis evidenced by interstitial collagen deposition. Treatment with GR-MD-02 reduced the mesangial matrix accumulation, which suggests the drug suppressed the production and/or accumulation of extracellular matrix components. Additionally, GR-MD-02 markedly reduced the area of interstitial fibrosis. These results demonstrate the anti-fibrotic efficacy of GR-MD-02 in the kidney and its therapeutic potential in diabetic nephropathy as well as other chronic kidney diseases. | |
|
News For GALT From The Last 14 Days Check below for free stories on GALT the last two weeks. |
|
|
| May 15, 2013 | | 10:03 EDT |  | GALT | Galectin Therapeutics to host a conference call
 Subscribe for More Information | | | May 10, 2013 | | 16:02 EDT |  | GALT | Galectin Therapeutics reports Q1 EPS (22c), one estimate (18c)
Subscribe for More Information | |
|
|
|
|
|
|
